Evolus, Inc. (EOLS): Shareholders' Equity
-$23.11M
As of 2025-12-31
-$30.90M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$23.11M | n/m | 2026-03-03, Balance as of period end |
| 2024-12-31 | $5.52M | n/m | 2026-03-03, Balance as of period end |
| 2023-12-31 | -$20.69M | n/m | 2026-03-03, Balance as of period end |
| 2022-12-31 | $18.50M | -77.4% | 2025-03-04, Balance as of period end |
| 2021-12-31 | $81.88M | n/m | 2023-03-08, Balance as of period end |
| 2020-12-31 | -$72.96M | n/m | 2022-03-03, Balance as of period end |
| 2019-12-31 | $79.46M | -5.8% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $84.38M | n/m | 2020-02-25, Balance as of period end |
| 2017-12-31 | -$75.54M | n/a | 2019-03-20, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | -$23.11M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | -$261.83M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $13.69M | n/m |
| CorMedix Inc. (CRMD) | 2025-12-31 | $405.31M | +378.8% |
| Harrow, Inc. (HROW) | 2025-12-31 | $52.45M | -24.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.02B | +22.5% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $433.90M | -22.8% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
Compare EOLS, IRWD, XERS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗